SCHEMBL5411580

SCHEMBL5411580

Cc1ccc(C=CS(=O)(=O)NC(=O)c2ccc(C)cc2C)c(C)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT1 P17948 3/20 0.51
FLT4 P35916 3/20 0.51
KDR P35968 3/20 0.51
SMN1; SMN2 Q16637 3/20 0.42
KMT2A Q03164 3/20 0.42
HTT P42858 2/20 0.42
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
AVPR2 P30518 1/20 0.41
GPR27 Q9NS67 1/20 0.41
KDM4E B2RXH2 2/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
LMNA P02545 1/20 0.40
POLB P06746 1/20 0.40
HSP90AA1 P07900 1/20 0.40
ALOX12 P18054 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
NFE2L2 Q16236 1/20 0.40
NPC1 O15118 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5411573 1.00 FLT1 (0.51) FLT1FLT4KDRSMN1; SMN2KMT2A
SCHEMBL4620080 0.86 FLT1 (0.56) FLT1FLT4KDRSMN1; SMN2NPC1
SCHEMBL4620071 0.86 FLT1 (0.56) FLT1FLT4KDRSMN1; SMN2NPC1
SCHEMBL5412813 0.85 FLT1 (0.51) FLT1FLT4KDRSMN1; SMN2KMT2A
SCHEMBL5412829 0.85 FLT1 (0.51) FLT1FLT4KDRSMN1; SMN2KMT2A
SCHEMBL4619085 0.84 FLT1 (0.48) FLT1FLT4KDRSMN1; SMN2KMT2A
SCHEMBL4619090 0.84 FLT1 (0.48) FLT1FLT4KDRSMN1; SMN2KMT2A
SCHEMBL5419489 0.84 FLT1 (0.43) FLT1FLT4KDRSMN1; SMN2MAPT
SCHEMBL5419497 0.84 FLT1 (0.43) FLT1FLT4KDRSMN1; SMN2MAPT
SCHEMBL5424981 0.83 ABCB1 (0.46) FLT1FLT4KDRKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 FLT1 4126/4885FLT4 4438/4885KDR 4332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.